Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bryostatin 1 - GPC Biotech

Drug Profile

Bryostatin 1 - GPC Biotech

Alternative Names: BMY 45618; Bryol; NSC 339555

Latest Information Update: 18 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arizona State University
  • Developer GPC Biotech AG
  • Class Antidementias; Antineoplastics; Macrocyclic compounds; Neuroprotectants; Vascular disorder therapies
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Chronic lymphocytic leukaemia; Graft-versus-host disease; Malignant melanoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Renal cancer

Most Recent Events

  • 15 Oct 2019 Aphios Corporation has patent protection for APH 0812 in China
  • 09 Mar 2004 Discontinued - Phase-II for Cancer in United Kingdom (Parenteral)
  • 09 Mar 2004 Discontinued - Phase-II for Chronic lymphocytic leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top